Page last updated: 2024-08-24

imiquimod and Dermatoses

imiquimod has been researched along with Dermatoses in 73 studies

Research

Studies (73)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	37 (50.68)	29.6817
2010's	21 (28.77)	24.3611
2020's	15 (20.55)	2.80

Authors

Authors	Studies
Goto, H; Habe, K; Iida, S; Kondo, M; Matsushima, Y; Naka, M; Nakai, Y; Nishii, M; Yamanaka, K	1
Bieler, T; Daiber, A; Karbach, S; Keller, K; Knopp, T; Kropp, A; Lagrange, J; Molitor, M; Münzel, T; Rauh, M; Ringen, J; Sies, K; Titze, J; Waisman, A; Wenzel, P; Wild, J	1
Correa Atella, G; Donato-Trancoso, A; Romana-Souza, B	1
Chen, Y; Li, X; Song, S; Wang, Y; Zhu, J	1
Wu, X; Xiang, S; Xiang, Y	1
Bai, D; Cheng, X; Hao, J; Li, Q; Lu, F; Sun, T; Zhang, B; Zhang, Y	1
Chen, JQ; Chen, XY; Cui, YZ; Fu, NC; Landeck, L; Man, XY; Wang, ZY; Xu, F; Yan, BX; Yang, XY; Zhou, Y	1
Banfi, G; Casciano, F; Gornati, L; Granucci, F; Guerrini, R; Marzola, E; Mingozzi, F; Montico, G; Protti, G; Reali, E; Secchiero, P; Volinia, S	1
Egusa, C; Harada, K; Hayakawa, K; Maeda, T; Okubo, Y	1
Chen, X; Lei, Y; Liu, Y; Lyu, C; Yang, Y; Ye, Y; Zhang, T; Zhou, X	1
Benoist, C; Hanna, BS; Hsu, YC; Mathis, D; Ortiz-Lopez, A; Sassone-Corsi, M; Shwartz, Y; Zarin, P	1
Chen, X; He, Y; Huang, X; Jia, H; Liu, T; Shan, W; Sun, R; Yang, Q	1
Chen, C; Chen, M; Chen, X; Kuang, Y; Li, J; Li, L; Liu, P; Peng, C; Su, J; Yan, B; Zhou, Y; Zhu, W	1
Cao, Z; Du, L; Han, C; Li, M; Liu, Z; Wei, J; Xu, Q; Zhang, C; Zhu, X	1
Chen, J; Ding, B; Huang, Z; Liang, L; Qian, Y; Zhou, Y; Zhu, L	1
Conti, F; Dika, E; Lacava, R; Lambertini, M; Neri, I; Patrizi, A; Pession, A; Scarfì, F; Veronesi, G	1
Dastidar, P; Roy, R	1
Cardoso, RM; Hansen, PR; Madsen, M; Nielsen, LB; Pedersen, TX; van Eck, M	1
Hu, R; Huang, G; Huang, J; Li, H; Liu, X; Xiao, S; Zhang, B; Zhao, W; Zheng, T	1
Chen, WR; Liu, P; Luo, M; Shi, L; Sroka, R; Stepp, H; Wang, B; Wang, X; Yang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, L; Zhang, Y; Zhou, F	1
Chen, M; Li, Y; Tang, F; Tong, M; Wen, H; Xiao, R; Zhang, G; Zhao, M	1
Pruthi, V; Raghuwanshi, N; Raj, U; Srivastava, AK; Varadwaj, P; Yadav, TC	1
Dang, Y; Geng, S; Guo, Y; Toyohara, JP	1
Baumgartner-Nielsen, J; Lorentzen, H	1
Altamura, D; Arkoumani, E; Hirbod, T; Simonacci, F; Verdolini, R	1
Guo, Q; Han, Y; Tan, G; Tang, Z; Xiong, H; Xu, W; Xu, Y; Zeng, F	1
Bayat, A; McGeorge, D; Sidgwick, GP	1
Ballegeer, M; Grine, L; Libert, C; Lienenklaus, S; Sanders, NN; Steeland, S; Van Ryckeghem, S; Vandenbroucke, RE; Weiss, S	1
Abadi, R; Abbas, O; Hanna, E	1
Di, T; Li, P; Liang, D; Liu, X; Wang, Y; Zhang, G; Zhao, J	1
Chen, O; Corley, SB; Morrell, DS; Pearlstein, MV	1
Allam, JP; Bieber, T; Novak, N; Yu, CF	1
Piérard, GE; Piérard-Franchimont, C	1
Avola, A; Borzomati, D; Degener, AM; Dianzani, C; Persichetti, P; Pierangeli, A	1
Kambe, N; Kim, YG; Matsue, H; Murakami, M; Nakamura, Y; Nishikomiri, R; Nishikomori, R; Núñez, G; Saito, M	1
A Gaspari, A; Rosen, T; Tyring, SK	1
Ganjian, S; Murase, JE; Ourian, AJ; Shamtoub, G; Wu, JJ	1
Koch, SN; Malone, ED; Torres, SM; Watson, JL; White, SD	1
Barr, KL; Fung, MA; Konia, TH	1
Gilardino, MS; Lee, J; Sinno, H; Tahiri, Y	1
Gaspari, AA; Grossberg, AL	1
Calvieri, S; Cantisani, C; Clerico, R; Lazic, T; Mattozzi, C; Richetta, AG	1
Dahl, MV	1
Stanley, MA	1
Berman, B; Poochareon, VN; Villa, AM	1
Hengge, UR; Meykadeh, N	1
Berman, B; Rigel, D	1
Chosidow, O; Dummer, R	1
Barton, S; Berman, B; Hengge, U	1
Johnson, R; Stockfleth, E	1
Salasche, S; Shumack, S	1
Benson, E	1
Sidbury, R	1
Albertini, G; Di Lernia, V; Ricci, C	1
Skinner, R	1
Sauder, DN	1
Sharpe, G; Smith, V	1
Marty, CL; Randle, HW; Walsh, JS	1
Wooten, JM	1
Chang, YC; Cook-Norris, R; Madkan, V; Sra, K; Tyring, S	1
Ezzell, TI; Fromowitz, JS; Ramos-Caro, FA	1
Goldenberg, G; Jorizzo, JL; Krowchuk, DP	1
Cartwright, N; Coyle, A; Fitzgerald, KA; Mitchell, JA; Silverman, N	1
Diwan, AH; Hearne, R; Polk, A; Prieto, VG; Treviño, J	1
Lio, P	1
Falagas, ME; Papadavid, E; Stratigos, AJ	1
Perry, CM; Wagstaff, AJ	1
Germain, M; Hamza, S; Skelton, H; Smith, K	1
Benton, EC	1
Behrendt, C; Esser, S; Goos, M; Hengge, UR; Meyer, T; Schultewolter, T; Stockfleth, E	1
Chapman, MS; Checketts, SR; Sparling, JD	1
Hermanns-Lê, T; Nikkels, AF; Petit, L; Piérard, GE; Uhoda, I	1
Eedy, DJ	1

Reviews

24 review(s) available for imiquimod and Dermatoses

Article	Year
A comprehensive evidence-based review on the role of topicals and dressings in the management of skin scarring. Archives of dermatological research, 2015, Volume: 307, Issue:6 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Bandages; Cicatrix; Humans; Imiquimod; Plant Extracts; Skin Diseases; Vitamins; Wound Healing	2015
Imiquimod in dermatology: an overview. International journal of dermatology, 2016, Volume: 55, Issue:8 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Carcinoma, Basal Cell; Condylomata Acuminata; Female; Humans; Imiquimod; Keratosis, Actinic; Male; Prognosis; Skin Diseases; Skin Neoplasms; Treatment Outcome	2016
Toll-like receptor 7 agonists and skin. Drug news & perspectives, 2008, Volume: 21, Issue:3 Topics: Aminoquinolines; Animals; Antineoplastic Agents; Humans; Imiquimod; Ligands; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Toll-Like Receptor 7	2008
Beyond a decade of 5% imiquimod topical therapy. Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:5 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Condylomata Acuminata; Humans; Imiquimod; Keratosis, Actinic; Papillomavirus Infections; Skin Diseases; Skin Neoplasms; Toll-Like Receptor 7	2009
Off-label indications for imiquimod. Dermatology online journal, 2009, May-15, Volume: 15, Issue:5 Topics: Adjuvants, Immunologic; Aminoquinolines; Antineoplastic Agents; Clinical Trials as Topic; Dermatologic Agents; Humans; Imiquimod; Interferon Inducers; Multicenter Studies as Topic; Retrospective Studies; Skin Diseases	2009
Treatment options for cutaneous pyogenic granulomas: a review. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2011, Volume: 64, Issue:9 Topics: Aminoquinolines; Anti-Infective Agents, Local; Antineoplastic Agents; Cautery; Cryotherapy; Curettage; Granuloma, Pyogenic; Humans; Imiquimod; Laser Therapy; Recurrence; Sclerotherapy; Silver Nitrate; Skin Diseases	2011
Topical antineoplastic agents in the treatment of mucocutaneous diseases. Current problems in dermatology, 2011, Volume: 40 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diterpenes; Fluorouracil; Humans; Imiquimod; Keratosis, Actinic; Mucositis; Mucous Membrane; Skin Diseases; Skin Neoplasms	2011
Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent patents on inflammation & allergy drug discovery, 2012, Volume: 6, Issue:1 Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Humans; Imiquimod; Interferons; Interleukin-12; Off-Label Use; Patents as Topic; Skin Diseases	2012
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clinical and experimental dermatology, 2002, Volume: 27, Issue:7 Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Disease Models, Animal; Humans; Imiquimod; Skin Diseases; Skin Neoplasms; Virus Diseases	2002
Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin therapy letter, 2002, Volume: 7, Issue:9 Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Female; Humans; Imiquimod; Male; Middle Aged; Skin Diseases	2002
Imiquimod: mode of action and therapeutic potential. Acta dermato-venereologica. Supplementum, 2003, Issue:214 Topics: Adjuvants, Immunologic; Aminoquinolines; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Imiquimod; Immune System; Papillomaviridae; Papillomavirus Infections; Skin Diseases; Skin Neoplasms	2003
Successful management of viral infections and other dermatoses with imiquimod 5% cream. Acta dermato-venereologica. Supplementum, 2003, Issue:214 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Carcinoma in Situ; Child; Condylomata Acuminata; Female; Humans; Imiquimod; Keloid; Male; Middle Aged; Molluscum Contagiosum; Skin Diseases; Virus Diseases; Vulvar Neoplasms	2003
Imiquimod 5% cream for the treatment of cutaneous lesions in immunocompromised patients. Acta dermato-venereologica. Supplementum, 2003, Issue:214 Topics: Adjuvants, Immunologic; Aminoquinolines; HIV Infections; Humans; Imiquimod; Immunocompromised Host; Organ Transplantation; Skin Diseases	2003
A review of imiquimod 5% cream for the treatment of various dermatological conditions. Clinical and experimental dermatology, 2003, Volume: 28 Suppl 1 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Condylomata Acuminata; Emollients; Female; Humans; Imiquimod; Male; Membrane Glycoproteins; Ointments; Receptors, Cell Surface; Skin Diseases; Toll-Like Receptors	2003
What's new in pediatric dermatology: update for the pediatrician. Current opinion in pediatrics, 2004, Volume: 16, Issue:4 Topics: Adjuvants, Immunologic; Aminoquinolines; Child; Clinical Trials as Topic; Dermatitis, Atopic; Hemangioma; Humans; Imiquimod; Immunoglobulins; Immunologic Factors; Immunosuppressive Agents; Infant; Molluscum Contagiosum; Skin; Skin Diseases; Stevens-Johnson Syndrome; Tacrolimus; Vitiligo; Warts	2004
Role of topical therapies in the management of cutaneous disease. Journal of cutaneous medicine and surgery, 2004, Volume: 8 Suppl 3 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Condylomata Acuminata; Dermatitis, Atopic; Dermatitis, Seborrheic; Humans; Hutchinson's Melanotic Freckle; Imiquimod; Keratosis; Melanoma; Membrane Glycoproteins; Receptors, Cell Surface; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Toll-Like Receptors	2004
Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions. Journal of cutaneous medicine and surgery, 2004, Volume: 8 Suppl 3 Topics: Adjuvants, Immunologic; Alefacept; Aminoquinolines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcineurin Inhibitors; CD11 Antigens; Dermatitis, Atopic; Glucocorticoids; Humans; Imiquimod; Interferons; Membrane Glycoproteins; Mycophenolic Acid; Psoriasis; Receptors, Cell Surface; Recombinant Fusion Proteins; Skin Diseases; Tacrolimus; Toll-Like Receptors	2004
Key developments in dermatology. The Practitioner, 2005, Volume: 249, Issue:1671 Topics: Administration, Topical; Aminoquinolines; Anti-Bacterial Agents; Dermatologic Agents; Dermatology; Humans; Imiquimod; Immunologic Factors; Practice Guidelines as Topic; Skin Diseases; Sunscreening Agents	2005
Current and potential uses of imiquimod. Southern medical journal, 2005, Volume: 98, Issue:9 Topics: Adjuvants, Immunologic; Aminoquinolines; Herpes Genitalis; Herpesvirus 2, Human; Humans; Imiquimod; Neoplasms; Skin Diseases; Tattooing	2005
Warts, molluscum and things that go bump on the skin: a practical guide. Archives of disease in childhood. Education and practice edition, 2007, Volume: 92, Issue:4 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Anti-Infective Agents; Cantharidin; Cryotherapy; Diagnosis, Differential; Disease Transmission, Infectious; Humans; Hyperthermia, Induced; Imiquimod; Irritants; Molluscum Contagiosum; Risk Factors; Salicylic Acid; Secondary Prevention; Skin Diseases; Treatment Outcome; Warts	2007
Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:11 Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Carcinoma, Basal Cell; Humans; Imiquimod; Photosensitivity Disorders; Precancerous Conditions; Skin Diseases; Skin Neoplasms	2007
Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs, 2007, Volume: 67, Issue:15 Topics: Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Basal Cell; Condylomata Acuminata; Humans; Imiquimod; Photosensitivity Disorders; Skin Diseases; Skin Neoplasms	2007
[Pharma clinics. Medication of the month. Imiquimod (Aldara): an immunomodulator for the skin]. Revue medicale de Liege, 2002, Volume: 57, Issue:2 Topics: Adjuvants, Immunologic; Aminoquinolines; Cytokines; Humans; Imiquimod; Macrophages; Skin Diseases	2002
Imiquimod: a potential role in dermatology? The British journal of dermatology, 2002, Volume: 147, Issue:1 Topics: Aminoquinolines; Condylomata Acuminata; Dermatologic Agents; Humans; Imiquimod; Interferon Inducers; Keratosis; Skin Diseases; Skin Neoplasms	2002

Trials

3 trial(s) available for imiquimod and Dermatoses

Article	Year
The efficacy of imiquimod 5% cream (Aldara® in the treatment of aural plaque in horses: a pilot open-label clinical trial. Veterinary dermatology, 2010, Volume: 21, Issue:5 Topics: Aminoquinolines; Animals; Ear Auricle; Ear Diseases; Female; Horse Diseases; Horses; Imiquimod; Interferon Inducers; Male; Pilot Projects; Skin Diseases	2010
Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2007, Volume: 33, Issue:12 Topics: Aminoquinolines; Biopsy; Dermatologic Agents; Female; Humans; Imiquimod; Immunohistochemistry; Keratosis; Male; Middle Aged; Photosensitivity Disorders; Pilot Projects; Rejuvenation; Signal Transduction; Skin; Skin Aging; Skin Diseases; Sunlight; Ultraviolet Rays	2007
Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. The British journal of dermatology, 2000, Volume: 143, Issue:5 Topics: Adolescent; Adult; Aminoquinolines; Antiviral Agents; Child; Female; Humans; Imiquimod; Interferon Inducers; Male; Middle Aged; Molluscum Contagiosum; Self Administration; Skin Diseases; Treatment Outcome; Warts	2000

Other Studies

46 other study(ies) available for imiquimod and Dermatoses

Article	Year
Psoriasis-like skin lesions occurring at remote sites after topical imiquimod. The Journal of dermatology, 2022, Volume: 49, Issue:10 Topics: Animals; Cytokines; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases	2022
Epicutaneous Application of Imiquimod to Model Psoriasis-Like Skin Disease Induces Water-Saving Aestivation Motifs and Vascular Inflammation. The Journal of investigative dermatology, 2022, Volume: 142, Issue:11 Topics: Animals; Disease Models, Animal; Estivation; Humans; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Water	2022
Dietary olive oil intake aggravates psoriatic skin inflammation in mice via Nrf2 activation and polyunsaturated fatty acid imbalance. International immunopharmacology, 2022, Volume: 108 Topics: Animals; Dermatitis; Diet; Disease Models, Animal; Fatty Acids, Unsaturated; Humans; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; Olive Oil; Psoriasis; Skin; Skin Diseases	2022
Potential mechanism of oral baicalin treating psoriasis via suppressing Wnt signaling pathway and inhibiting Th17/IL-17 axis by activating PPARγ. Phytotherapy research : PTR, 2022, Volume: 36, Issue:10 Topics: Animals; Disease Models, Animal; Estrogens; Flavonoids; Imiquimod; Interleukin-17; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; PPAR gamma; Protein Kinases; Psoriasis; Skin; Skin Diseases; Th17 Cells; Tumor Necrosis Factor-alpha; Wnt Signaling Pathway	2022
Sinomenine Suppressed Keratinocyte Proliferation and Imiquimod-Induced Psoriasis-Like Dermatitis by Regulating lncRNA XIST. Skin pharmacology and physiology, 2022, Volume: 35, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; RNA, Long Noncoding; Skin Diseases	2022
Eupatilin inhibits keratinocyte proliferation and ameliorates imiquimod-induced psoriasis-like skin lesions in mice via the p38 MAPK/NF-κB signaling pathway. Immunopharmacology and immunotoxicology, 2023, Volume: 45, Issue:2 Topics: Animals; Cell Proliferation; Disease Models, Animal; Imiquimod; Interleukin-17; Interleukin-23; Interleukin-6; Keratinocytes; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Psoriasis; Skin; Skin Diseases; Tumor Necrosis Factor-alpha	2023
Mupirocin blocks imiquimod-induced psoriasis-like skin lesion by inhibiting epidermal isoleucyl-tRNA synthetase. Cell communication and signaling : CCS, 2022, 11-22, Volume: 20, Issue:1 Topics: Animals; Humans; Imiquimod; Isoleucine-tRNA Ligase; Mice; Mice, Inbred C57BL; Mupirocin; Psoriasis; Skin Diseases	2022
CCR4 European journal of immunology, 2023, Volume: 53, Issue:4 Topics: Animals; Arthritis, Psoriatic; CD8-Positive T-Lymphocytes; Humans; Imiquimod; Inflammation; Mice; Mice, Inbred C57BL; Psoriasis; Receptors, Antigen, T-Cell; Receptors, CCR4; Skin Diseases	2023
Topical application of imatinib mesylate ameliorated psoriasis-like skin lesions in imiquimod-induced murine model via angiogenesis inhibition. Experimental dermatology, 2023, Volume: 32, Issue:6 Topics: Animals; Disease Models, Animal; Humans; Imatinib Mesylate; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Vascular Endothelial Growth Factor A	2023
Fufang Shengdi mixture alleviates psoriasis-like skin inflammation via promoting Annexin-A proteins expression. Journal of ethnopharmacology, 2023, Aug-10, Volume: 312 Topics: Animals; Annexins; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Tumor Necrosis Factor-alpha	2023
Treg cells require Izumo1R to regulate γδT cell-driven inflammation in the skin. Proceedings of the National Academy of Sciences of the United States of America, 2023, 04-04, Volume: 120, Issue:14 Topics: Animals; Dermatitis; Imiquimod; Inflammation; Mice; Psoriasis; Receptors, Cell Surface; Skin; Skin Diseases; T-Lymphocytes, Regulatory	2023
Specific Activation of CB2R Ameliorates Psoriasis-Like Skin Lesions by Inhibiting Inflammation and Oxidative Stress. Inflammation, 2023, Volume: 46, Issue:4 Topics: Animals; Cytokines; Disease Models, Animal; Imiquimod; Inflammation; Kelch-Like ECH-Associated Protein 1; Keratinocytes; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; Oxidative Stress; Psoriasis; Skin; Skin Diseases	2023
Lysophosphatidylcholine facilitates the pathogenesis of psoriasis through activating keratinocytes and T cells differentiation via glycolysis. Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:7 Topics: Animals; Cell Differentiation; Disease Models, Animal; Imiquimod; Keratinocytes; Lysophosphatidylcholines; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases	2023
Qingre Lishi Decoction ameliorates imiquimod-induced psoriasis-like skin lesions in SKH-1 mice by regulating the Treg-DC-Th17 axis and inhibiting MAPK-mediated DC maturation. Journal of ethnopharmacology, 2024, Jan-10, Volume: 318, Issue:Pt A Topics: Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Psoriasis; Skin; Skin Diseases; T-Lymphocytes, Regulatory; Th17 Cells	2024
Di-(2-ethylhexyl) phthalate aggravates psoriasis-like skin lesions: In vitro and in vivo evaluation. Toxicology and applied pharmacology, 2023, Nov-15, Volume: 479 Topics: Animals; Diethylhexyl Phthalate; Humans; Imiquimod; Inflammation; Mice; p38 Mitogen-Activated Protein Kinases; Psoriasis; Skin; Skin Diseases	2023
Imiquimod cream in pediatric patients: Recommendations, adverse events, and controversies. Dermatologic therapy, 2019, Volume: 32, Issue:6 Topics: Child; Humans; Imiquimod; Ointments; Skin Diseases	2019
Supramolecular Synthon Approach in Developing Anti-Inflammatory Topical Gels for In Vivo Self-Delivery. Chemistry (Weinheim an der Bergstrasse, Germany), 2017, Nov-07, Volume: 23, Issue:62 Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Gels; Imiquimod; Mice; RAW 264.7 Cells; Salicylates; Skin Diseases; X-Ray Diffraction	2017
Imiquimod-Induced Psoriasis-Like Skin Lesions Do Not Accelerate Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. The American journal of pathology, 2018, Volume: 188, Issue:6 Topics: Animals; Atherosclerosis; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Knockout; Psoriasis; Receptors, LDL; Skin Diseases	2018
MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease. Frontiers in immunology, 2018, Volume: 9 Topics: Animals; Cytokines; Dual Specificity Phosphatase 1; Imiquimod; Inflammation Mediators; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Severity of Illness Index; Skin; Skin Diseases	2018
Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. Journal of biophotonics, 2019, Volume: 12, Issue:2 Topics: Adolescent; Adult; Aged; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Imiquimod; Immunotherapy; Male; Middle Aged; Phototherapy; Skin Diseases; Temperature; Treatment Outcome; Warts; Young Adult	2019
Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 109 Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Indole Alkaloids; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Quinazolines; Signal Transduction; Skin; Skin Diseases; Th17 Cells; Toll-Like Receptor 7	2019
Structure-based drug designing and identification of Woodfordia fruticosa inhibitors targeted against heat shock protein (HSP70-1) as suppressor for Imiquimod-induced psoriasis like skin inflammation in mice model. Materials science & engineering. C, Materials for biological applications, 2019, Feb-01, Volume: 95 Topics: Animals; Disease Models, Animal; Gold; Heat-Shock Proteins; Humans; Imiquimod; Metal Nanoparticles; Mice; Molecular Docking Simulation; Psoriasis; Skin Diseases; Woodfordia	2019
Successful treatment of verruciform xanthoma with imiquimod. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:4 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Biopsy, Needle; Child, Preschool; Female; Follow-Up Studies; Humans; Imiquimod; Immunohistochemistry; Rare Diseases; Skin Diseases; Time Factors; Treatment Outcome; Vulvar Diseases; Xanthomatosis	2013
Imiquimod 5%: a successful treatment for pseudolymphoma. Acta dermato-venereologica, 2014, Volume: 94, Issue:4 Topics: Administration, Topical; Aminoquinolines; Humans; Imiquimod; Immunologic Factors; Male; Middle Aged; Pseudolymphoma; Recurrence; Skin Diseases; Treatment Outcome	2014
Histologic features mimicking mycosis fungoides induced by imiquimod, 5%: a potential pitfall for dermatopathologists. JAMA dermatology, 2014, Volume: 150, Issue:11 Topics: Adjuvants, Immunologic; Aged, 80 and over; Aminoquinolines; Drug Eruptions; Humans; Imiquimod; Keratosis, Actinic; Male; Mycosis Fungoides; Skin Diseases	2014
Glycyrrhizin ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice and inhibits TNF-α-induced ICAM-1 expression via NF-κB/MAPK in HaCaT cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2015, Volume: 35, Issue:4 Topics: Aminoquinolines; Animals; Cell Adhesion; Cell Line; Cell Survival; Female; Glycyrrhizic Acid; Humans; Imiquimod; Inflammation; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Monocytes; NF-kappa B; Phosphorylation; Psoriasis; Signal Transduction; Skin Diseases; Tumor Necrosis Factor-alpha; Up-Regulation	2015
Topical imiquimod yields systemic effects due to unintended oral uptake. Scientific reports, 2016, Jan-28, Volume: 6 Topics: Administration, Oral; Administration, Topical; Aminoquinolines; Animals; Disease Models, Animal; Gastrointestinal Tract; Imiquimod; Interferon Type I; Mice; Phenotype; Psoriasis; Skin Diseases	2016
Multi-glycoside of Tripterygium wilfordii Hook. f. ameliorates imiquimod-induced skin lesions through a STAT3-dependent mechanism involving the inhibition of Th17-mediated inflammatory responses. International journal of molecular medicine, 2016, Volume: 38, Issue:3 Topics: Aminoquinolines; Animals; CD4-Positive T-Lymphocytes; Cytokines; Gene Expression; Glycosides; Imiquimod; Immunohistochemistry; Inflammation; Inflammation Mediators; Interleukin-17; Mice, Inbred BALB C; Phosphorylation; Phytotherapy; Protective Agents; Psoriasis; Reverse Transcriptase Polymerase Chain Reaction; Skin; Skin Diseases; STAT3 Transcription Factor; T-Lymphocytes, Regulatory; Th17 Cells; Tripterygium	2016
Verrucae Planae Within Previous Xenograft Sites of Burn Wounds. Pediatric dermatology, 2017, Volume: 34, Issue:3 Topics: Administration, Topical; Aminoquinolines; Burns; Child, Preschool; Follow-Up Studies; Heterografts; Humans; Imiquimod; Immunocompromised Host; Injury Severity Score; Male; Rare Diseases; Severity of Illness Index; Skin Diseases; Skin Transplantation; Treatment Outcome; Warts	2017
[How I treat... some skin disorders from the angle of innate immunity]. Revue medicale de Liege, 2008, Volume: 63, Issue:12 Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Infective Agents; Cathelicidins; Defensins; Humans; Imiquimod; Immunity, Innate; Skin; Skin Diseases; Toll-Like Receptors; Treatment Outcome	2008
Intra-anal condyloma: surgical or topical treatment? Dermatology online journal, 2008, Dec-15, Volume: 14, Issue:12 Topics: Administration, Topical; Adult; Aminoquinolines; Anal Canal; Anus Diseases; Condylomata Acuminata; Humans; Imiquimod; Laser Therapy; Male; Ointments; Retreatment; Skin Diseases; Treatment Outcome	2008
Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. The Journal of experimental medicine, 2009, May-11, Volume: 206, Issue:5 Topics: Aminoquinolines; Carrier Proteins; Caspases; Familial Mediterranean Fever; Histamine; Humans; Imiquimod; Interferon Inducers; Interleukin-6; Lipopolysaccharides; Lymphocyte Activation; Mast Cells; Neutrophil Infiltration; Neutrophils; NLR Family, Pyrin Domain-Containing 3 Protein; Skin Diseases; Urticaria	2009
Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall. Journal of cutaneous pathology, 2011, Volume: 38, Issue:4 Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Diagnosis, Differential; Humans; Imiquimod; Immunity, Cellular; Keratosis, Actinic; Male; Skin Diseases	2011
Imiquimod: a cytokine inducer. Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:4 Suppl Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Condylomata Acuminata; Cytokines; Humans; Imiquimod; Interferon Inducers; Papillomaviridae; Papillomavirus Infections; Skin Diseases; Skin Diseases, Viral; Tumor Virus Infections; Warts	2002
[Topical immunomodulators in dermatology]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2003, Volume: 54, Issue:7 Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Asthma; Autoimmune Diseases; Bowen's Disease; Child; Cyclopropanes; Dermatitis, Atopic; Dinitrochlorobenzene; Female; Follow-Up Studies; Herpes Simplex; Humans; Imidazoles; Imiquimod; Immunity, Cellular; Immunocompromised Host; Immunoglobulin A; Immunosuppressive Agents; Lichen Sclerosus et Atrophicus; Male; Molluscum Contagiosum; Papillomavirus Infections; Precancerous Conditions; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Time Factors; Warts	2003
Introduction: immunotherapy for dermatological conditions. Acta dermato-venereologica. Supplementum, 2003, Issue:214 Topics: Adjuvants, Immunologic; Aminoquinolines; Humans; Imiquimod; Immunotherapy; Skin Diseases	2003
Imiquimod: potential risk of an immunostimulant. The Australasian journal of dermatology, 2004, Volume: 45, Issue:2 Topics: Adjuvants, Immunologic; Adolescent; Aminoquinolines; Drug Antagonism; Female; Humans; Imiquimod; Immunosuppressive Agents; Papillomaviridae; Papillomavirus Infections; Recurrence; Skin Diseases; Spondylitis; Uterine Cervical Dysplasia; Vulvar Diseases; Warts	2004
Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream. Journal of the European Academy of Dermatology and Venereology : JEADV, 2004, Volume: 18, Issue:5 Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Cheek; Diagnosis, Differential; Female; Humans; Imiquimod; Keratoacanthoma; Middle Aged; Skin Diseases	2004
Eruptive epidermoid cysts resulting from treatment with imiquimod. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2005, Volume: 31, Issue:7 Pt 1 Topics: Administration, Topical; Aged; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Dermatologic Agents; Female; Humans; Imiquimod; Retinoids; Skin Diseases; Skin Neoplasms; Treatment Outcome	2005
Imiquimod. Southern medical journal, 2005, Volume: 98, Issue:9 Topics: Adjuvants, Immunologic; Aminoquinolines; Cytokines; Humans; Imiquimod; Neoplasms; Skin Diseases	2005
Recurrent pyogenic granuloma treated with topical imiquimod. Journal of the American Academy of Dermatology, 2006, Volume: 54, Issue:5 Suppl Topics: Administration, Topical; Aminoquinolines; Angiogenesis Inhibitors; Fingers; Granuloma, Pyogenic; Humans; Imiquimod; Male; Middle Aged; Recurrence; Skin Diseases; Treatment Outcome	2006
Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. The Journal of dermatological treatment, 2006, Volume: 17, Issue:2 Topics: Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Fingers; Granuloma, Pyogenic; Humans; Imiquimod; Male; Middle Aged; Recurrence; Skin Diseases	2006
TOLLing away in Brazil. Nature immunology, 2006, Volume: 7, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Aminoquinolines; Animals; Antineoplastic Agents; Antiprotozoal Agents; Brazil; Carcinoma, Basal Cell; Condylomata Acuminata; Diaminopimelic Acid; Drosophila melanogaster; Drosophila Proteins; Gene Expression Regulation; Gram-Negative Bacteria; Humans; Imiquimod; Immunity, Innate; Infections; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Melanoma; Mice; Models, Immunological; Molecular Structure; Peptidoglycan; Protozoan Infections; Radiation Chimera; RNA Helicases; Signal Transduction; Skin Diseases; Skin Neoplasms; Substrate Specificity; Toll-Like Receptor 7; Toll-Like Receptors	2006
Atypical lymphocytic reaction with epidermotropism and lymphocytic vasculopathic reaction (lymphocytic vasculitis) after treatment with imiquimod. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:5 Suppl Topics: Adjuvants, Immunologic; Aged; Aminoquinolines; Carcinoma, Basal Cell; Female; Humans; Imiquimod; Lymphocytes; Skin Diseases; Skin Neoplasms; Vasculitis	2006
Treatment of warts with immune response modifiers. The British journal of dermatology, 2000, Volume: 143, Issue:5 Topics: Aminoquinolines; Antiviral Agents; Humans; Imiquimod; Interferon Inducers; Skin Diseases; Warts	2000
Imiquimod for plantar and periungual warts. Cutis, 2001, Volume: 68, Issue:6 Topics: Administration, Topical; Adolescent; Aminoquinolines; Female; Follow-Up Studies; Foot Dermatoses; Humans; Imiquimod; Nail Diseases; Skin Diseases; Treatment Outcome; Warts	2001